Innovation1 Biotech appoints Samuel Knipper as CFO and interim CEO

Innovation1 Biotech Inc.

Samuel Knipper, 30, appointed CFO effective Feb 23, 2025; also named interim CEO under Brio agreement.
Knipper designated by Brio Financial Group; company pays Brio $8,500/month plus expenses for controller and reporting services.
Appointment lasts approximately 120 days or until close of a SPAC merger or exchange listing, whichever comes first.
Knipper previously senior associate at Calabrese Consulting and SEC reporting manager at Brio Financial Group.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Samuel Knipper

Chief Financial Officer

Innovation1 Biotech Inc.

Effective: 2025-02-23
Filed: February 27, 2025, 6:59 PM ET

On February 23, 2025, Innovation1 Biotech Inc. (the “Company”) appointed Samuel Knipper to serve as chief financial officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Samuel Knipper was appointed as Chief Financial Officer at Innovation1 Biotech Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On February 23, 2025, Innovation1 Biotech Inc. (the “Company”) appointed Samuel Knipper to serve as chief financial officer of the Company.

View on SEC.gov

Source: SEC EDGAR

accession 0001753926-25-000312

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.